WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584401
CAS#: 107430-03-5
Description: Moflomycin is an anthracycline derivative that exhibits a higher antileukemic activity compared to other anthracyclines, such as daunorubicin and doxorubicin. The higher antileukemic activity of this compound are from greater stimulation of topoisomerase II-mediated DNA cleavage and higher molecular stability induced by the presence of an iodine atom.
Hodoodo Cat#: H584401
Name: Moflomycin
CAS#: 107430-03-5
Chemical Formula: C25H25IO10
Exact Mass: 612.05
Molecular Weight: 612.370
Elemental Analysis: C, 49.03; H, 4.12; I, 20.72; O, 26.13
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Moflomycin; F 860191; F-860191; F860191
IUPAC/Chemical Name: 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxymethyl)-, (7S,9S)-
InChi Key: IJWZCUDUUDYUBR-IWGZIANCSA-N
InChi Code: InChI=1S/C25H25IO10/c1-9-18(28)23(33)17(26)24(35-9)36-13-7-25(34,8-27)6-12-14(13)22(32)16-15(21(12)31)19(29)10-4-2-3-5-11(10)20(16)30/h2-5,9,13,17-18,23-24,27-28,31-34H,6-8H2,1H3/t9-,13-,17+,18-,23-,24-,25-/m0/s1
SMILES Code: O=C(C1=C2C(O)=C3C[C@](CO)(O)C[C@H](O[C@H]4[C@H](I)[C@@H]([C@H]([C@H](C)O4)O)O)C3=C1O)C5=CC=CC=C5C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 612.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Andrivon W, Monneret C, Nafziger J, Florent JC, Guillosson JJ. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance. Leuk Res. 1998 Aug;22(8):719-25. PubMed PMID: 9680099.
2: Andrivon W, Callais F, Nafziger J, Monneret C, Guillosson JJ. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity. Mutat Res. 1995 Oct;344(3-4):135-40. PubMed PMID: 7491131.
3: Florent JC, Genot A, Monneret C. Synthesis and antitumor activity of new anthracyclines. J Antibiot (Tokyo). 1989 Dec;42(12):1823-30. Erratum in: J Antibiot (Tokyo) 1990 Mar;43(3):C-1. PubMed PMID: 2621164.
4: Nafziger J, Auclair C, Florent JC, Guillosson JJ, Monneret C. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity. Leuk Res. 1991;15(8):709-13. PubMed PMID: 1654481.
5: Andrivon W, Saucier JM, Auclair C, Monneret C, Florent JC, Guillosson JJ, Nafziger J. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity. Leuk Res. 1996 Feb;20(2):119-26. PubMed PMID: 8628010.
